BiomX Inc.
https://www.biomx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BiomX Inc.
Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
Seventure Reaffirms Microbiome Confidence With New €200m Fund
With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.
Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- BiomX Ltd.
- Chardan Healthcare Acquisition Corp.
- MBcure
- RondinX Ltd.